Turning Selected Sites into Study-Ready Sites

With Persistent AI-Enabled Clinical Study Start-Up & Site Activation

The Site Is Selected. Activation Is Still at Risk.

Selecting a promising site is only the beginning. Before enrollment can start, sponsors must align contracts, ethics and regulatory submissions, essential documents, investigator readiness, technology access and operational dependencies. When these activities are managed across fragmented systems and teams, small exceptions become activation delays. A 2026 Bain & Company survey of 120 clinical trial professionals found that twice as many sites expect their capacity to worsen over the next three years as expect it to improve. For sponsors, that pressure translates into missed milestones, higher operational effort, longer study timelines and delayed evidence for regulatory and commercial decisions.

Activation Needs Intelligence & Execution Layer

AI can help teams move beyond static readiness checklists by connecting contract, submission, document, investigator and operational signals; predicting which dependencies will put activation dates at risk; and directing the next best action to the right owner. The opportunity is not simply to select better sites, but to continuously turn selected sites into study-ready capacity.

McKinsey reports that applying AI/ML across clinical-development assets and therapeutic areas has compressed development timelines by an average of six months per asset. Realizing that value at study start-up requires more than predictive insight: teams need connected workflows that expose blockers early, coordinate intervention and keep activation decisions governed.

That is difficult to scale when readiness data is fragmented across paper, spreadsheets and siloed platforms. A 2026 Clinical Trial Technology report notes that 56% of clinical-trial documentation still originates on paper. Without integrated data, connected execution and clear governance, AI becomes another point solution rather than a means to accelerate site activation.

Turning a selected site into a study-ready site is not something another isolated AI tool can do. It requires an intelligence and execution layer that connects readiness signals, workflows and decisions across the start-up journey. Persistent provides that layer by helping teams expose blockers early, coordinate the next best action and prevent small exceptions from becoming activation delays.

Setting up Intelligent Study Start-up Operation

Persistent AI-enabled Clinical Study Start-Up and Site Activation solution creates a connected intelligence and execution layer across the start-up lifecycle. It covers feasibility, budgets and contracts, ethics and regulatory submissions, essential documents, investigator readiness, site activation and early recruitment and retention. It brings the signals that predict site performance into a single, governed view, so teams can select sites with greater confidence, anticipate risk earlier and act before delays take hold.

• Select sites on evidence, not optimism: Combine protocol fit, enrollment history, patient availability, investigator experience, competing studies, site capacity, quality indicators and operational performance to identify the sites most likely to activate on time and meet enrollment targets.
• Continuously assess activation readiness: Track regulatory, ethics, contracting, documentation and investigator dependencies continuously, rather than treating readiness as a one-time checkpoint after feasibility.
• Predict risk before it becomes delay: Detect emerging bottlenecks, forecast activation timelines and enrollment risk and prioritize the sites where intervention will have the greatest impact.
• Accelerate document and Trial Master File (TMF) readiness: Automatically classify essential documents, extract and validate key data and track completeness to reduce manual review and strengthen inspection readiness.
• Coordinate work with governed AI agents: Automate routine follow-ups, document checks and task routing and escalate exceptions, all within defined roles, controls and human approval points.
• Turn exceptions into next best actions: Prioritize issues by their impact on study timelines, recommend the appropriate response and route it to the right owner at the right site.
• Extend intelligence beyond activation: Monitor early recruitment and retention signals to flag under-enrollment and early signs of patient drop-out before they compromise the study plan.
• Give leaders one operational view: Surface portfolio status, site readiness, bottlenecks, risk exposure and intervention priorities through role-based insights.

Built to Scale Responsibly

Persistent combines life sciences domain expertise, data engineering, predictive AI, intelligent automation and agentic orchestration to operationalize AI across the study start-up journey.

Our solution integrates with existing clinical platforms such as CTMS and eTMF, establishes reusable data and workflow foundations and embeds controls for GxP and 21 CFR Part 1 compliance, audit trails and human approvals directly into each workflow. Clinical teams retain control of consequential decisions, while AI continuously analyzes signals, coordinates routine work and escalates exceptions with context.

From Selected to Ready

The shift from selected to ready begins with a more complete, continuously updated view of each site. Instead of relying on a single feasibility decision, study teams can follow the signals that matter as activation progresses—from regulatory and contracting dependencies to investigator, document and TMF readiness. That makes emerging activation, recruitment and retention risks visible earlier, while there is still time to intervene.

Earlier visibility also changes how teams respond. Rather than spending time reconciling spreadsheets, chasing routine updates and reacting after milestones slip, they can focus attention on the sites and issues most likely to affect the study plan. Connected workflows help route the right action across regulatory, contracting, documentation and operational teams, reducing manual coordination and avoidable delays.

Over time, this creates more than a faster start-up process. It establishes a more predictable, data-driven clinical operations model in which AI can scale through connected data and governed workflows, while clinical teams retain control of consequential decisions. The result is a clearer path from choosing a site to making it genuinely ready to support the study.

Accelerate Site Activation with Persistent

Talk to Persistent team about building an AI-enabled study start-up operation that identifies risk earlier, accelerates action and scales with confidence.